Ipsen to present two late-breaking sessions at AASLD on new PBC data supporting IQIRVO®’s long-term efficacy, safety and mechanistic insights in fatigue
IPSEN (OTCMKTS:IPSEY) had its "buy" rating reaffirmed by analysts at Deutsche Bank Aktiengesellschaft.
Ipsen Launches Educational Initiative to Support Teens and Young Adults Moving From Pediatric to Adult Healthcare
EQT Life Sciences' ImCheck Therapeutics to be acquired by Ipsen in a transaction valued at up to EUR 1 billion
Ipsen delivers strong sales in the first nine months of 2025 and further upgrades its full-year guidance